[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"waldenstrom-macroglobulinaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:waldenstrom-macroglobulinaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,84,131,158,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100651875","phase-3-evaluation-of-iopofosine-i-131-vs-r-cd-in-wm-patients-100651875",false,"NCT07766421","Evaluation of Iopofosine I 131 vs. R-CD in WM Patients","An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor","Inclusion Criteria:\n\n* Histologically and serologically confirmed diagnosis of WM.\n* Received at least one prior therapy for WM.\n* Received treatment with a BTKi (including covalent BTKi or non-covalent BTKi).\n* Symptomatic disease progression requiring therapy. Specifically, participant must meet one of the following:\n\n  a. Biochemical progression or progression by imaging: i. ≥ 25% increase in serum IgM levels with a minimum increase of 500 mg\u002FdL from nadir. If serum IgM is used to support progression, 2 sequential measurements are required. ii. Any new lesion (\\>1.5 cm in any axis) or unequivocal evidence of an increase by \\>50% in any axis to \\>1.5 cm in size of previously involved extramedullary disease sites from their nadir measurements. Progression by imaging does not require re-confirmation for eligibility.\n\n  b. Clinical signs or symptoms as determined by the investigator (e.g., constitutional symptoms (fatigue, fevers, night sweats, etc.), hyperviscosity syndrome, demyelinating peripheral neuropathy, cytopenias, organomegaly, etc.).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.\n* Participant is ≥ 18 years of age.\n* Life expectancy ≥ 6 months.\n* Presence of elevated total serum IgM (2x above institutional upper limit of normal (ULN)). Participants with extramedullary disease only may not be enrolled.\n* Participant must meet the following hematological laboratory criteria:\n\n  1. Platelets ≥ 75,000\u002FuL.\n  2. Absolute neutrophil count (ANC) ≥ 1000\u002FuL\n  3. Hemoglobin ≥ 8 g\u002FdL, that can be maintained by packed red blood cell (PRBC) transfusions\n  4. Estimated glomerular filtration rate ≥ 30 mL\u002Fmin\u002F1.73 m2 (as calculated using the CKD-EPI 2021 formula) OR serum creatinine ≤ 1.5 x ULN\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN\n  6. Bilirubin \\\u003C 1.5 × ULN, except for patients with Gilbert's syndrome, who may be enrolled if bilirubin is \\\u003C 3 x ULN or direct bilirubin is \\\u003C 1.5 x ULN.\n* Patient who has undergone autologous stem cell transplant must be at least one year from the date of hematopoietic recovery.\n* Patient must express willingness and ability to comply with scheduled study visits, treatment plans, laboratory tests, and other study procedures.\n* Patient or their legally authorized representative must have the ability to understand and provide signed informed written consent before the initiation of any study-related procedures.\n* Female patients of childbearing potential, defined as all women physiologically capable of becoming pregnant, must have a negative serum or urine beta human chorionic gonadotropin (b-hCG) pregnancy test result within one week prior to first dose of study treatment and agree to use a highly effective method of contraception during the study and for 12 months following administration of the last dose of study treatment.\n* Sexually active males, including those who have had a vasectomy, must agree to use a condom during intercourse while receiving iopofosine I 131 or R-CD and for three months after the last dose of iopofosine I 131 or R-CD.\n\nExclusion Criteria:\n\n* Receipt of:\n\n  1. Anti CD-20 MoAb \\\u003C 6 months prior to study drug administration.\n  2. Any conventional cytotoxic chemotherapy ≤ four weeks prior to study drug administration.\n  3. Non-anti CD20 MoAb therapy for the treatment of WM ≤ three months prior to study drug administration. i. The only exception to this is for those patients who have documented evidence of progression while receiving non-anti CD20 MoAb therapy.\n  4. BTKi therapy ≤ 48 hours prior to study drug administration.\n  5. Any investigational agents ≤ two weeks or five half-lives, whichever is shorter, prior to study drug administration.\n* Evidence of Bing Neel disease or disease transformation at the time of study entry.\n* Evidence of or suspected of having Myelodysplastic Syndrome (MDS) based upon laboratory and bone marrow testing at the time of trial entry. Note: this includes suspicion of or presence of MDS or CHIP mutation as per the trial screening bone marrow biopsy.\n* Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia, that in the opinion of the investigator might be exacerbated by study treatment.\n* Prior external-beam radiation therapy resulting in greater than 20% of total bone marrow receiving greater than 20 Gy. For estimation purposes, the following bone marrow percentages can be used:\n\n  1. Vertebral bodies: Cervical 0.5%, thoracic 1%, lumbar 2% per vertebral body\n  2. Hemipelvis (ilium, acetabulum, ischium): 13% per side\n  3. Sacrum: 10%\n  4. Skull: 12%\n  5. Scapula: 5% per side\n  6. Ribs: 4% per side\n  7. Femur: 3% per side\n* Prior total body irradiation.\n* Patients with presence of second malignancies in addition to WM. However, patients with the following malignancies within the past two years may enroll as long as there is no evidence of disease: non-melanoma skin cancers only requiring topical treatment or surgical excision; melanoma in situ; localized cancer of the prostate with current prostate-specific antigen of \\\u003C 0.1 µg\u002FmL; treated cervical carcinoma in situ; or ductal\u002Flobular carcinoma in situ of the breast.\n* Ongoing chronic immunosuppressive therapy.\n* Any other concomitant serious illness or organ system dysfunction (including cardiac and pulmonary dysfunction) that in the opinion of the Investigator would either compromise patient safety or interfere with the evaluation of the safety of the study drug.\n* Major surgery (e.g., intra-abdominal, intra-thoracic, or intra-pelvic) ≤ 4 weeks prior to study drug administration, or lack of recovery from side effects of such surgery. Video-assisted thoracic surgery (VATS) and mediastinoscopy, placement of central venous catheter, endoscopy procedures, and percutaneous tissue biopsies will not be considered major surgery and patients can receive study drug ≥ one week after these procedures.\n* History of hypersensitivity to thyroid protection medication (e.g., potassium iodide, Lugol's solution, etc.), murine compounds, or anti CD-20 MoAbs (e.g., rituximab).\n* History of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product.\n* History of hypersensitivity to any components of dexamethasone, including sodium sulfites.\n* Ongoing urinary outflow obstruction or systemic fungal infection.\n* Known history of human immunodeficiency virus (HIV).\n* Known history or active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) defined by positive polymerase chain reaction (PCR). Hepatitis patients receiving antiviral therapy (e.g., entecavir) who do not have a positive PCR are eligible.\n* Presence of active infection within 72 hours prior to initiation of study treatment. Patients with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible as long as there is no evidence of active infection and the antibiotics, antifungals, or antivirals are not included on the list of prohibited medications.\n* Pregnancy or breast-feeding.","ALL","18 Years",{"count":19,"type":20},219,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is:\n\n• Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse.\n\nParticipants will:\n\n* Be randomly assigned to received either iopofosine I 131 or R-CD.\n* If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3 months long).\n* If assigned to R-CD, it will be administered for up to six cycles, and each cycle is 3-weeks long\n* Visit the clinic once every 3 weeks for checkups and testing.\n* Report any side effects or new medications.",[26,27,28,29,30],"Waldenstrom Macroglobulinaemia","Waldenstrom Macroglobulinemia","Waldenstrom's Macroglobulinaemia Refractory","Waldenstrom Macroglobulinemia With Nodal Disease","Waldenstrom's Macroglobulinemia Recurrent",[32,33,34],"iopofosine I 131","CLR 131","waldenstroms","NOT_YET_RECRUITING","2026-08-11",{"date":38,"type":39},"2026-08-14","ACTUAL",{"date":41,"type":20},"2026-12",{"date":43,"type":20},"2035-01",{"name":45,"class":46},"Cellectar Biosciences, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100641819","connected-blood-pressure-monitoring-in-patients-with-hematologic-malignancies-initiating-covalent-btk-inhibitors-100641819","NCT07592481","Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors","HEMO-CONNECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma\n* Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients\n* Affiliation with a social security system\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known cognitive impairment\n* No internet access\n* Individuals under guardianship, curatorship, or legal protection",{"count":55,"type":20},40,[57],"NA","This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.",[60,61,26,62,63,64],"Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma ( FL)","Lymphoplasmacytic Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma",[66,67,68,69,70,71,72,73],"BTK inhibitor","Hypertension","Telemonitoring","Connected device","Blood pressure","Lymphoid malignancies","Advanced practice nursing","Cardio-oncology","2026-06-18",{"date":76,"type":39},"2026-06-22",{"date":78,"type":20},"2026-07-01",{"date":80,"type":20},"2027-12-31",{"name":82,"class":83},"Centre Hospitalier de la côte Basque","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100557911","phase-1-synkir-310-for-relapsedrefractory-b-nhl-100557911","NCT06544265","SynKIR-310 for Relapsed\u002FRefractory B-NHL","A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Adult 18 years of age and older.\n* Histologically confirmed diagnosis of B-NHL before enrollment.\n* Must have received prior CAR T or were unwilling\u002Funable to receive prior CAR T.\n* Must have refractory or relapsed disease after receiving 2 prior lines of therapies.\n* If relapsed\u002Frefractory post-auto-SCT, then must have undergone auto-SCT at least 6 months prior to enrollment.\n* If relapsed\u002Frefractory disease after allogeneic stem cell transplant (allo SCT) then must have undergone allo-SCT at least 6 months prior to enrollment and without evidence of graft versus host disease, and expectation to remain off immunosuppressive therapy through duration of trial\n* Measurable disease at time of enrollment: At least one measurable lesion per Lugano Response Criteria (Cheson et al., 2014) or measurable disease per IWWM-11 response criteria (Treon 2023) for Waldenström macroglobulinemia patients.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Previously treated with any investigational agent within 30 days prior to screening.\n* Any previous or concurrent malignancy, with the following exceptions:\n\nAdequately treated non-melanoma skin cancer such as basal cell or squamous cell carcinoma; carcinoma-in-situ (e.g., cervix, bladder, breast) treated curatively and without evidence of recurrence for at least 3 years prior to enrollment or adequately treated melanoma skin cancer in-situ; any other malignancy which has been completely treated and remains in complete remission for ≥ 5 years prior to enrollment. Completely treated prostate cancer with prostate-specific antigen (PSA) level \\\u003C 1.0 may also be permitted.\n\n* Use of systemic immunosuppressive drugs within 4 weeks prior to study entry, or anticipated use of systemic immunosuppressive agents through end of study, with the exception of non-T cell targeting agents prior to leukapheresis\n* Known immunodeficiency disease , with the exception of hypoglobulinemia\n* History or presence of active or clinically relevant primary central nervous system (CNS) disorder, such as seizure, encephalopathy, cerebrovascular ischemia\u002Fhemorrhage, cerebellar disease, or any autoimmune disease with CNS involvement. For primary CNS disorders that have recovered or are in remission, participants without recurrence within 2 years of planned study enrollment may be included.\n* Uncontrolled hypertension, history of myocarditis or congestive heart failure, unstable angina, serious uncontrolled cardiac arrhythmia, or myocardial infarction within 6 months prior to study entry.\n* Any active uncontrolled systemic fungal, bacterial or viral infection.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":92,"type":20},36,[94],"PHASE1","This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed\u002Frefractory B-NHL.",[97,98,64,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,27,26],"B Cell Lymphoma","NHL, Adult","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Aggressive B-Cell Non-Hodgkin Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma","HGBL With MYC and BCL2 and\u002For BCL6 Rearrangements","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","Large B-cell Lymphoma","T-Cell\u002FHistiocyte Rich Lymphoma","Non-hodgkin Lymphoma,B Cell","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Epstein-Barr Virus Positive DLBCL, Nos","Follicular Lymphoma Grade 3B","DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation","High Grade B-Cell Lymphoma, Not Otherwise Specified","Follicular Lymphoma Grade 3","Marginal Zone Splenic Lymphoma","DLBCL","RECRUITING","2026-04-08",{"date":123,"type":39},"2026-04-14",{"date":125,"type":39},"2024-11-01",{"date":127,"type":20},"2028-12",{"name":129,"class":46},"Verismo Therapeutics",5,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":130},"100629460","phase-4-blood-dose-a-platform-trial-evaluating-dose-optimization-in-hematological-diseases-100629460","NCT07474961","BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.","A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol","BLOOD-dose","Inclusion Criteria:\n\n* Participants of any sex who are at least 18 years of age at the time of providing informed consent.\n* Participant diagnosed with a haematological disease, i.e. any disorder that primarily affects the blood, bone marrow, the lymphatic system and\u002For blood-forming organs.\n* Should be eligible for participation in at least one of the currently active domains.\n* Capable of giving signed informed consent for each applicable DSA(s). By consenting to a domain, participants also consent to participation in BLOOD-dose.\n\nExclusion Criteria:\n\n* The participant tient is expected to live less than 3 months, as judged by the investigator.\n* Any condition that, in the opinion of the investigator, impairs the participant's ability to understand trial procedures, provide informed consent and\u002For interfere with participation and\u002For compliance in the trial.\n\nDomain eligibility criteria: each domain has its own specific eligibility criteria detailed in each DSA.",{"count":140,"type":20},400,[142],"PHASE4","BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.\n\nThe BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions.\n\nNew domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.",[26,145],"Multiple Myeloma",[145,147,26,148],"Platform Trial","Dose-optimization","2026-03-14",{"date":151,"type":39},"2026-03-16",{"date":153,"type":20},"2027-03",{"date":155,"type":20},"2036-12",{"name":157,"class":83},"Anne Louise Tølbøll Sørensen",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":167,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100605265","this-study-aims-to-clarify-the-prevalence-and-characteristics-of-neuropathy-along-with-associated-paraclinical-findings-in-patients-with-waldenstrms-macroglobulinemia-wm-in-a-cohort-of-wm-patients-to-optimize-the-diagnostic-process-100605265","NCT07160270","This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process","Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment","Inclusion Criteria:\n\n* Diagnosis of Waldenström's Macroglobulinemia with symptoms of peripheral neuropathy for further clinical investigation.\n\nExclusion Criteria:\n\n* Investigated with no sign of peripheral neuropathy",{"count":166,"type":20},90,"3 Years","OBSERVATIONAL","Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Neuropathy is a frequent morbidity in Waldenström's macroglobulinemia (WM), a specific type of lymphoma caused by infiltration of clonal lymphoplasmocytic B cells in the bone marrow with the presence of IgM paraprotein. WM associated neuropathy is largely undescribed. The few existing studies are mostly retrospective indicating the neuropathy has a heterogenic pathophysiology and diverse clinical appearance from mild sensory neuropathy to aggressive with loss of ambulation and development of chronic neuropathic pain within weeks to months.\n\nWith treatment of WM the speed of the disease progression including the related neuropathy can be halted. Few studies and clinical experience indicate that the nerve damage induced by WM might remit if treatment is initiated early in the course of the disease. Thus, there is need for timely interventions to reduce chronic disabilities. However, even for an experienced neurologist, it can be difficult to identify whether the neuropathy is caused by WM or other causes where treatment is not indicated.\n\nThis project aims to investigate the prevalence and underlying mechanisms of neuropathy in patients with WM to help speed up the diagnostic process and thus help slow down the irreversible nerve damage that these patients experience.",[26,171],"Peripheral Neuropathies","2025-08-29",{"date":174,"type":39},"2025-09-08",{"date":176,"type":39},"2025-05-14",{"date":178,"type":20},"2025-12-30",{"name":180,"class":83},"Rigshospitalet, Denmark",1,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":191,"studyType":168,"phases":4,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":181},"100558385","early-assessment-of-lymphoma-treatment-response-using-phased-variant-analysis-with-next-generation-sequencing-100558385","NCT06550427","Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing","Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing","Inclusion Criteria:\n\n* • Pathology proven lymphoma\n\n  * Age ≥ 18 years old\n\nExclusion Criteria:\n\n* none",{"count":190,"type":20},200,"2 Years","Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma. LBCL's aggressive nature manifests through extranodal involvement, severe symptoms, and relative refractoriness to therapies, leading to a 5-year overall survival rate of 60-70% across developed countries and poorer outcomes in high-risk patients with primary refractory disease. Chemoimmunotherapy remains the primary treatment for LBCL, requiring comprehensive assessment through clinical and imaging examinations, biomarkers, and molecular testing. Currently, computed tomography (CT) and positron emission tomography (PET) scans are the standard modalities for treatment response evaluation, though their radioactive nature calls for the development of safer alternatives. Circulating tumor DNA (ctDNA) analysis has emerged as a promising field, providing insights into tumor molecular characteristics, clinical status, and treatment response by analyzing DNA fragments released from tumor cells into the bloodstream. Dynamic monitoring of ctDNA during treatment can effectively gauge therapeutic efficacy-decreasing ctDNA concentrations suggest successful treatment, while increasing levels may indicate treatment failure or tumor recurrence. The detection of ctDNA has been much improved through advances in next-generation sequencing (NGS) technologies, particularly taking advantage of analyzing phased variants, consecutive gene mutations on the same chromosome, enhances the sensitivity and specificity.",[194,195,196,26],"Lymphoma","Hodgkin Lymphoma","T-cell Lymphoma",[194,198,199,200,201],"NGS","Phased Variant","Early Response Assessment","Early Outcome","2025-06-15",{"date":204,"type":39},"2025-06-17",{"date":206,"type":39},"2024-08-09",{"date":208,"type":20},"2027-07-31",{"name":210,"class":83},"National Taiwan University Hospital"]